Abstract
Prostate cancer is the second most common primary tumor affecting men worldwide. Among them, 10-20% develop castration resistant prostate cancer (CRPC). Ga-PSMA-PET/CT is an important theranostic agent for the evaluation of CRPC to assess the feasibility of treatment with Lu-PSMA-617 which is a novel therapeutic agent. Interestingly, in certain cases, we have observed non-PSMA-avid lesions despite raised sPSA levels. In this regard, we present a case of cocktail therapy applied using Lu-PSMA-617 and Lu-EDTMP therapy in a 38-year-old male CRPC patient with both soft tissue and extensive skeletal metastases.
MeSH terms
-
Adult
-
Dipeptides / administration & dosage
-
Dipeptides / therapeutic use*
-
Edetic Acid / analogs & derivatives
-
Gallium Isotopes
-
Gallium Radioisotopes
-
Heterocyclic Compounds, 1-Ring / administration & dosage
-
Heterocyclic Compounds, 1-Ring / therapeutic use*
-
Humans
-
Male
-
Oligopeptides
-
Organometallic Compounds / therapeutic use*
-
Organophosphorus Compounds / therapeutic use*
-
Positron Emission Tomography Computed Tomography*
-
Prostate-Specific Antigen
-
Prostatic Neoplasms, Castration-Resistant / diagnostic imaging
-
Prostatic Neoplasms, Castration-Resistant / drug therapy*
-
Radiopharmaceuticals / administration & dosage
-
Radiopharmaceuticals / therapeutic use*
Substances
-
Dipeptides
-
Gallium Isotopes
-
Gallium Radioisotopes
-
Heterocyclic Compounds, 1-Ring
-
Oligopeptides
-
Organometallic Compounds
-
Organophosphorus Compounds
-
PSMA-617
-
Radiopharmaceuticals
-
gallium 68 PSMA-11
-
lutetium ethylenediaminetetramethylene phosphonic acid
-
Edetic Acid
-
Prostate-Specific Antigen